NCT02859324View on ClinicalTrials.gov

A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 20, 2016

Primary Completion Date

March 27, 2020

Study Completion Date

March 27, 2020

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

CC-122

DRUG

Nivolumab

Trial Locations (14)

144

Istituto Nazionale Tumori Regina Elena, Roma

8035

Hospital Universitario Vall D Hebron, Barcelona

10016

NYU Langone Medical Center, New York

13273

Institut Paoli Calmettes, Marseille

20089

IRCCS - Istituo Clinico Humanitas - Humanitas Cancer Center, Milan

27100

Fondazione IRCCS Policlinico San Matteo, Pavia

28034

Hospital Ramon y Cajal, Madrid

28041

Hospital 12 de Octubre, Madrid

31059

Institut Universitaire du Cancer IUCT - Oncopole, Toulouse

32610

University of Florida, Gainesville

35200

Centre Eugene Marquis, Rennes

75251

Mary Crowley Cancer Research, Dallas

94805

Institut Gustave Roussy Hematologie, Villejuif

90095-1752

UCLA Division of Hematology Oncology, Los Angeles

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02859324 - A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter